Presentation is loading. Please wait.

Presentation is loading. Please wait.

Aggressive Therapy for Hypercholesterolemia: Data, Strategy and Outcomes Timothy A. Denton, M.D. High Desert Heart Institute Victorville, CA.

Similar presentations


Presentation on theme: "Aggressive Therapy for Hypercholesterolemia: Data, Strategy and Outcomes Timothy A. Denton, M.D. High Desert Heart Institute Victorville, CA."— Presentation transcript:

1 Aggressive Therapy for Hypercholesterolemia: Data, Strategy and Outcomes Timothy A. Denton, M.D. High Desert Heart Institute Victorville, CA

2

3

4 Can you identify these?

5 VLDL B100 CI CII CIII E IDL B100 E LDL B100 Chylomicrons B100 CI CII CIII E AI AII AIV B48 Remnants B48 E HDL2 AI AII AI AII HDL3 HDL1 AI AII

6 Standard Approach to LDL Management Event Diet Exercise DietDrugs 6 months

7 A Probabilistic Equation P(success | overall population) = P(success | ideal population) * P(compliance | overall population)

8 1 - Diet 2 - Exercise 3 - Drugs 4 - Partial ileal bypass 5 - Portacaval shunting 6 - Apheresis adsorption column (LDL apheresis) plasma exchange double membrane dextran sulfate precipitation immunoabsorption 7 - Liver transplantation Methods for Modifying Cholesterol Levels

9 Diet

10 Ornish D, et al. Lancet 1990;336:129 Lifestyle Heart Trial

11 Ornish D, et al. Lancet 1990;336:129 Lifestyle Heart Trial

12 Ornish D, et al. Lancet 1990;336:129 Lifestyle Heart Trial Intervention group LDL after 1 year Mean = 93 mg/dl + 43 mg/dl NCEP Goal 55.3% 44.7%

13 Biosphere

14 Biosphere 2 “Isolated, confined environment”, 2 years 8 subjects Green and yellow vegetables Animal products of 1 egg, 112 g of meat, 500 cc of goat milk per WEEK All had consistent weight loss for 2 years Blood samples q 1-2 months Verdery, et al. Arch Intern Med 1998;158:900 Biosphere2 Dietary Restriction

15 Verdery, et al. Arch Intern Med 1998;158:900 Biosphere2 Dietary Restriction

16 Mean = 58 + 7 mg/dl LDL after 2 years NCEP Goal Verdery, et al. Arch Intern Med 1998;158:900 Biosphere2 Dietary Restriction 100% 0%

17 Dietary “Success”

18 Exercise

19 Effect of Fitness on Survival Blair JAMA 1989;262:2395

20 Effect of Fitness on Survival Blair JAMA 1989;262:2395

21 Sesso et al. Circ 2000;102:975-980 Harvard Alumni Health Study 4.2 kJ = 1 kcal 500 Cal 500-1000 Cal1000-2000 Cal2000-3000 Cal >3000 Cal

22 Effect of Exercise on Lipids Kokkinos Arch Int Med 1995:155:415  2906 men  age 30-64 years  exercise treadmill test to exhaustion  classified into 6 groups based on average miles run per week

23 Effect of Exercise on Lipids Kokkinos Arch Int Med 1995:155:415

24 Mean = 121 + 29 mg/dl NCEP Goal Verdery, et al. Arch Intern Med 1998;158:900 Running 21-60 Miles per Week 22.9% 77.1%

25 Cholesterol-Lowering Drugs

26 Cholesterol Modifying Agents

27 Achievement of NCEP Goal Brown, JACC 1998; 32:665 atorva = atorvastatin (Lipitor) simva = simvastatin (Zocor) lova = lovastatin (Mevacor) fluva = fluvastatin (Lescol) colest = colestipol (Colestid)

28 Achievement of NCEP Goal Brown, JACC 1998; 32:665 P=NS

29 Statins Jones et al. Am J Cardiol2003;92:152 Prava Simva Atorv Rosuva

30 Lancet 1994;344:1383 4S Survival Curves

31 MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) 122 centers -- Europe, North America, South Africa, Australasia adults with chest pain x15 min exclusion coronary revascularization planned cholesterol >270 mg% Q-wave MI 3 months CABG, 6 months PTCA, 4 weeks MI LBBB, CHF III, other drugs, DM, preg Schwartz JAMA 2001;285:1711

32 MIRACL P=0.048 Schwartz JAMA 2001;285:1711 Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Ischemic events

33 MIRACL P=0.02 Schwartz JAMA 2001;285:1711 Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering CVA

34 Pitt, B. et al. N Engl J Med 1999;341:70-76 Cumulative Incidence of First Ischemic Events 341 pts CCS 0,I PTCA vs MedRx

35 REVERSAL P=0.02 Nissen JAMA 2004;291:1071 Reversal of Atherosclerosis with Aggressive Lipid Lowering DB Random atorv v. prava (79 v. 110) IV US Atheroma vol

36 ASCOTT-LLA P=0.0005 Nissen JAMA 2004;291:1071 Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm 19,342 HTN + 3 RF Tchol < 250 Atorva v placebo trial stopped 3.3 yrs P=0.024 P=0.0005 P=0.16

37 ACCESS Smith Phamacoeconomics 2003;21:13 Atorvastatin Comparative Cholesterol Efficacy and Safety Study 3,387 54 weeks Atorva, fluva, lova, prava, simva titrate to LDL < 100 Drug Total Cost to Goal Atorva683.37 fluva+211.35 lova+607.96 Prava+424.60 simva+95.74

38 Baycol (cerivastatin) 12/1/2000 -- FDA approves 0.8 mg 3/30/2001 -- FDA warning about metabolism 8/1/01 -- 31 US deaths, 19 lone drug, 12 in combination 8/8/2001 -- Bayer removes Baycol from US Market

39 When should we START therapy?

40 CHAMP Fonarow, AJC 2001;87:819 (Cardiac Hospitalization Atherosclerosis Management Program) UCLA Observational / Interventional AHA Guidelines Standard orders, education, DC planning Phone follow-up

41 CHAMP Fonarow, AJC 2001;87:819

42 CHAMP

43 When should we START therapy? AS SOON AS POSSIBLE!!!!

44 But my hospitalized patient’s LDL is at goal.

45 Brugada, Cardiology 1996;87:194 Original paper reports total cholesterol Converted to LDL by assuming LDL = 0.67 * total cholesterol

46 But my hospitalized patient’s LDL is at goal. Not for long…

47 Aggressive Approach to LDL Management Event Drug therapy Diet Exercise X

48 The Guidelines

49 How often do we provide these therapies?

50 State Standings Jencks et al. JAMA 2000;284:1670 Ranked by CV indicators, mammog, immune, etc

51 Effects of Various Cardiac Therapies

52

53

54 The End


Download ppt "Aggressive Therapy for Hypercholesterolemia: Data, Strategy and Outcomes Timothy A. Denton, M.D. High Desert Heart Institute Victorville, CA."

Similar presentations


Ads by Google